RINVOQ can
relieve PsA
joint
and skin*
symptoms

*RINVOQ is not approved to treat plaque psoriasis.

For adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.

For adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.

Proven in PsA clinical studies:

The majority taking RINVOQ saw significant improvement in PsA joint pain, stiffness, and swelling at 12 weeks.

Many people felt RAPID RELIEF as fast as

2

WEEKS

The majority taking RINVOQ saw significant improvement in PsA joint pain, stiffness, and swelling at 12 weeks.

20% improvement in PsA symptoms when used with or without csDMARDs. Doctors adjusted supportive PsA medicines as needed at Week 16 or 36.

Most people still taking RINVOQ continued to see improvement in PsA symptoms, even at

3

YEARS

In this less rigorous part of the study, patients and physicians were aware of RINVOQ treatment, which may have influenced the results at 3 years.

RINVOQ helped stop irreversible joint damage for a majority of patients at 24 weeks.

Many saw no further joint damage, even at

5

YEARS

2

RINVOQ helped stop irreversible joint damage for a majority of patients at 24 weeks.

At 5 years, results were measured in a less rigorous part of the study and may have been influenced by patients and physicians knowing the patients were on RINVOQ. 

Individual results may vary.

Select Important Safety Information

RINVOQ may cause serious side effects, including:

  • Serious Infections, Cancer and Immune System Problems, and Blood Clots.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Increased risk of major cardiovascular events, such as heart attack, stroke, or death in people age 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.

Safety Considerations

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below.

75%
2

75%

CLEARER SKIN IS POSSIBLE

for people with itchy, painful PsA skin plaques

Cursor icon used to drag a slider element on the page

Drag the slider to see the difference.

Illustration of PsA skin plaques on an elbow after treatment

After 4 months

Before

Illustration of PsA skin plaques on an elbow before treatment

Illustration of skin clearance for people with moderate to severe PsA skin plaques. Individual results may vary.

RINVOQ has not been studied in and is not indicated for the treatment of plaque psoriasis.

Proven in PsA clinical studies, RINVOQ can also:

Hand icon indicating swelling from PsA
Hand icon indicating swelling from PsA

Relieve swelling and tenderness in places like fingers, elbows, and toes

Shoe icon indicating ease in doing things with PsA

Make it easier to do everyday things, like tying shoes

Battery icon indicating fatigue
Battery icon indicating fatigue

Significantly reduce PsA fatigue to help you get through your day

See RINVOQ results in action

Refusing to let PsA symptoms steal her artistic spark, Anna partnered with her rheumatologist to make a change.

Anna did not participate in clinical studies for RINVOQ.

Individual results may vary.

NEXT PAGE